Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress

Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Oppenheimer analysts maintained their $75 price target for Revolution Medicines, Inc. (NASDAQ:RVMD) and reaffirmed their Outperform rating on June 3. Updates from competing KRAS initiatives that were given at this year’s ASCO meeting coincide with the reaffirmation.

The Oppenheimer analysts pointed out that smaller datasets would provide difficulties for Revolution’s rivals in the G12Di arena for pancreatic ductal adenocarcinoma (PDAC). That said, Revolution’s Phase 3 trials in second-line and beyond are currently recruiting for PDAC and non-small cell lung cancer (NSCLC.

With the initiation of registrational trials in the adjuvant context and first-line metastatic PDAC, focus is now turning to front-line prospects. Potential pipeline updates that could further inform Revolution’s development plan are anticipated by the analysts for the second half of the year.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage biotech company that develops cancer medications that target RAS, a major category of genetic abnormalities that are frequently present in difficult-to-treat cancers.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.